(0.34%) 5 117.12 points
(0.31%) 38 356 points
(0.38%) 15 988 points
(-0.86%) $83.13
(5.82%) $2.04
(0.44%) $2 357.50
(0.46%) $27.66
(3.92%) $958.25
(-0.21%) $0.933
(-0.39%) $10.98
(-0.55%) $0.796
(1.66%) $93.40
@ $5.59
発行日: 15 2月 2024 @ 03:54
リターン: -33.66%
前回のシグナル: 2月 14 - 23:30
前回のシグナル:
リターン: 3.36 %
Live Chart Being Loaded With Signals
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally...
Stats | |
---|---|
本日の出来高 | 1.93M |
平均出来高 | 1.84M |
時価総額 | 386.64M |
EPS | $0 ( 2024-02-28 ) |
次の収益日 | ( $-0.660 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.970 |
ATR14 | $0.0130 (0.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Jordan Erica | Sell | 2 392 | Common Stock |
2024-03-15 | Sjuts Dustin S | Sell | 2 967 | Common Stock |
2024-03-18 | Sjuts Dustin S | Sell | 9 211 | Common Stock |
2024-03-15 | Moxie Dwight | Sell | 3 269 | Common Stock |
2024-03-18 | Moxie Dwight | Sell | 8 125 | Common Stock |
INSIDER POWER |
---|
64.41 |
Last 97 transactions |
Buy: 2 720 068 | Sell: 629 333 |
ボリューム 相関
Revance Therapeutics Inc 相関
10 最も正の相関 | |
---|---|
SYKE | 0.944 |
SPRB | 0.923 |
BRACU | 0.922 |
XLRN | 0.921 |
PIRS | 0.918 |
ATCX | 0.918 |
MESA | 0.915 |
VRME | 0.915 |
JFIN | 0.913 |
OVID | 0.907 |
10 最も負の相関 | |
---|---|
AHPI | -0.934 |
TUEM | -0.902 |
VERA | -0.881 |
ARDS | -0.865 |
CYTO | -0.86 |
NAKD | -0.852 |
LCAP | -0.85 |
CFV | -0.844 |
JRJC | -0.843 |
APM | -0.837 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Revance Therapeutics Inc 相関 - 通貨/商品
Revance Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $234.04M |
総利益: | $145.98M (62.38 %) |
EPS: | $-3.83 |
FY | 2023 |
収益: | $234.04M |
総利益: | $145.98M (62.38 %) |
EPS: | $-3.83 |
FY | 2022 |
収益: | $132.57M |
総利益: | $80.90M (61.03 %) |
EPS: | $-4.90 |
FY | 2021 |
収益: | $77.80M |
総利益: | $54.39M (69.91 %) |
EPS: | $-4.17 |
Financial Reports:
No articles found.
Revance Therapeutics Inc
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。